T lymphocytes restrain spontaneous metastases in permanent dormancy

Cancer Research

Volumn 74, Issue 7, 2014, Pages 1958-1968

  Romero, Irene ^a   Garrido, Cristina ^b   Algarra, Ignacio ^c   Collado, Antonia ^a   Garrido, Federico ^a,b   Garcia Lora, Angel M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER GROWTH; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR LOCALIZATION;

ANIMALS; CELL LINE, TUMOR; FIBROSARCOMA; G(M1) GANGLIOSIDE; H-2 ANTIGENS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; T-LYMPHOCYTES;

EID: 84897410699     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2084     Document Type: Article

References (50)

1. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72:3125-30.
2. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
3. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106-16.
4. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001;83:117-58.
5. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
6. Gallina G,Dolcetti L, Serafini P,DeSanto C,Marigo I, ColomboMP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:2777-90.
7. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
8. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;195: 346-55.
9. Carretero R,WangE, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonmediated rejection genes. Int J Cancer 2012;131:387-95.
10. Garrido C, Algarra I, Maleno I, Stefanski J, Collado A, Garrido F, et al. Alterations of HLAclass I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother 2010;59:13-26.
11. Aguirre Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002;21:2513-24.
12. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008;13:507-18.
13. KhazaieK, Prifti S, Beckhove P,GriesbachA, Russell S, Collins M, et al. Persistence of dormant tumor cells in the bone marrow of tumor cellvaccinated mice correlates with long-Term immunological protection. Proc Natl Acad Sci U S A 1994;91:7430-4.
14. Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 2001;166:699-703.
15. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
16. Chen LP, Suzuki Y, Liu CM, Wheelock EF. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: dependence of interleukin 2 on induced interferon-gamma and on tumor necrosis factor for its antitumor effects. Cancer Res 1990;50:1368-74.
17. Saudemont A, Quesnel B. In a model of tumor dormancy, long-Term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004;104:2124-33.
18. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, et al. Cancer dormancy. VII. A regulatory role for CD8+T cells and IFNgamma in establishing and maintaining the tumor-dormant state. J Immunol 1999;162:2842-9.
19. Muller M, Gounari F, Prifti S, Hacker HJ, Schirrmacher V, Khazaie K. EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. Cancer Res 1998;58:5439-46.
20. Suzuki Y, Chen LP, Liu CM, Morita T, Wheelock EF. Immune regulation of the L5178Y murine tumor-dormant state: induction of cell-And soluble factor-mediated inhibition of tumor cell growth by tumor necrosis factor and gamma-interferon. Cancer Res 1989; 49:2028-33.
21. Sagalowsky AI, Molberg K. Solitary metastasis of renal cell carcinoma to the contralateral adrenal gland 22 years after nephrectomy. Urology 1999;54:162.
22. Louis DN, Hochberg FH. Cerebral primitive neuroectodermal tumor in an adult, with spinal cord metastasis after 18-year dormancy. J Neurooncol 1990;9:77-80.
23. Cozar JM, Aptsiauri N, Tallada M, Garrido F, Ruiz-Cabello F. Late pulmonary metastases of renal cell carcinoma immediately after posttransplantation immunosuppressive treatment: a case report. J Med Case Rep 2008;2:111.
24. Stewart TH, Hollinshead AC, Raman S. Tumour dormancy: initiation, maintenance and termination in animals and humans. Can J Surg 1991;34:321-5.
25. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000;70:1747-51.
26. Valente M, Furian L, Rigotti P. Organ donors with small renal cancer: report of 3 cases. Transplant Proc 2012;44:1846-7.
27. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003;348: 567-8.
28. Garrido A, Perez M, Delgado C, Garrido ML, Rojano J, Algarra I, et al. Influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/c tumor. Exp Clin Immunogenet 1986;3:98-110.
29. Perez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, et al. A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 1990;46:258-61.
30. Romero I, Martinez M, Garrido C, Collado A, Algarra I, Garrido F, et al. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol 2012;227:367-79.
31. Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010;16:974-5.
32. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793-804.
33. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011;11:135-41.
34. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.
35. Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, et al. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol 2011;90:777-85.
36. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010;120: 2030-9.
37. Garrido C, Romero I, Berruguilla E, Cancela B, Algarra I, Collado A, et al. Immunotherapy eradicates metastases with reversible defects inMHC class I expression. Cancer Immunol Immunother 2011;60:1257-68.
38. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001;91:109-19.
39. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 2003;106:521-7.
40. Garrido F, Algarra I, Garcia-Lora AM. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother 2010;59:1601-6.
41. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notchand hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22: 373-88.
42. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012;490:412-6.
43. Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. NK and CD8+ T cellmediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004;109:499-506.
44. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, et al. Natural killer cells activated byMHCclass I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003;19: 561-9.
45. Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, et al. DC-NK cell cross talk as a novel CD4+T-cell-independent pathway for antitumor CTL induction. Blood 2005;106:338-44.
46. Trambley J, Bingaman AW, Lin A, Elwood ET, Waitze SY, Ha J, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999;104:1715-22.
47. Moore ML, Chi MH, Goleniewska K, Durbin JE, Peebles RS Jr. Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection. Viral Immunol 2008;21:327-39.
48. Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 2012;33:687-93.
49. Sleeman JP. The metastatic niche and stromal progression. Cancer Metastasis Rev 2012;31:429-40.
50. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23:573-81.